Abstract High-resolution manometry (HRM) and peroral endoscopic myotomy (POEM) have contributed significantly to the field of esophageal motility disorders in recent years. The development of HRM has categorized various esophageal motility disorders with a focus on a diverse range of manometric anomalies. Additionally, the Chicago classification criteria is widely used for manometric diagnosis. Moreover, POEM was introduced as a minimally invasive radical therapy for achalasia and shows promise for other spastic esophageal motility disorders as well. POEM has also enabled a transluminal endoscopic approach for determining the histology of the esophageal muscle layer, which is expected to assist in elucidating the etiology of disorders associated with esophageal motility. The purpose of this review is to update the diagnosis, pathology, and treatment of esophageal motility disorders, with a focus on the recent advances in this field.
Introduction
Achalasia is a well-known primary esophageal motility disorder. The disease concept was first described more than 300 years ago as a food blockage in the esophagus [1] . In 1927, the Greek term ''achalasia'' was first used by Hurst, and characterized as a ''failure of relaxation'' of the lower esophageal sphincter (LES) after swallowing [2] . With the advent of esophagography and endoscopy, the old symptom-based disease concept could be characterized more objectively, such as observing aperistalsis, esophageal dilation, poor emptying of barium in the esophageal body, minimal LES opening, and a ''bird-beak'' appearance through radiography, and endoscopically by confirming a dilated esophagus with retained saliva, liquid, and undigested food in the absence of a mucosal fibrotic stricture or tumor [3] . The appearance of rosette-like esophageal folds, or a pinstripe pattern are characteristic endoscopic findings in achalasia [4, 5] . Moreover, conventional manometry was developed, and it defined a manometric pattern of achalasia as insufficient relaxation of the LES, and loss of esophageal peristalsis. Although the clinical diagnosis and treatment of achalasia have been systematized, its pathophysiology and etiology are yet unknown [6] [7] [8] [9] [10] .
In conventional manometry, a 'dent sleeve sensor' was necessary for the precise evaluation of LES function. This is because a pseudo-relaxation of the LES due to postdeglutitive esophageal shortening cannot be ruled out with conventional manometry. A dent sleeve sensor is 6 cm in length and allows the LES to move relative to it without a loss of recorder contact [11, 12] . One drawback is that an infused catheter system is applied to it (Fig. 1a) , making the preparation and procedure of the manometry examination complicated. Additionally, the catheter is connected to large equipment used for analyzing the change of water flow and numerically quantifying it, thereby preventing easy bedside use [13] . The development of high-resolution manometry (HRM) was started in the 1990s with Clouse's studies [14, 15] , and then applied in 2000 in a clinical setting [16] . HRM has closely-spaced pressure sensors, usually 1-1.5 cm apart, with 20-36 circumferential channels per catheter (Fig. 1b) , and utilizes a water infused catheter as well as a transducer catheter [17] . In a HRM transducer catheter, each pressure sensor directly senses changes in intraluminal pressure, and transforms it into an electrical signal. The development of an 'e-sleeve' application in HRM (Fig. 2 ) provides the maximum pressure over a 6-cm distance, similar to the dent sleeve sensor in conventional manometry, and allows for better characterization of LES pressurization and relaxation. Pressure topography plotting in HRM enables visualization of deglutitive esophageal function, and it allows for more rapid positioning of the catheter array. HRM can better define the manometric variation of esophageal motility disorders [18] [19] [20] . In 2012, the Chicago classification (CC) was developed and used as the HRM-based standardized criteria of esophageal motility disorders [21] . More recently, the v3.0 was published with further revisions [22] .
In 2007, submucosal endoscopic esophageal myotomy was described [23] , and peroral endoscopic myotomy (POEM) was reported in 2010 as a new minimally invasive endoscopic treatment for achalasia (Fig. 3a) [24] . We subsequently introduced endoscopic muscle layer biopsy during POEM (peroral esophageal muscle biopsy [POEMb] ) to investigate the histology (Fig. 3b) [25] . This review is to update the diagnosis, pathology, and treatment of esophageal motility disorders, with a focus on the recent advances in this field (Fig. 4) .
High-resolution manometry
The display of HRM (Fig. 2 ) depicts esophageal pressure activity from the pharynx to the stomach (longitudinal axis), and from swallowing to the post-deglutitive period (horizontal axis). To assess deglutitive LES relaxation, integrated relaxation pressure (IRP) is used as a parameter. The loss of LES relaxation is the most important element for the diagnosis of achalasia. The IRP is measured after deglutitive upper sphincter relaxation from the anticipation of esophago-gastric junction (EGJ) relaxation until peristaltic wave arrival. An e-sleeve measurement is taken within 10 s and the 4 s during which the e-sleeve value is least determined. The next parameter is distal latency (DL), which has an important role for the assessment of the esophageal contraction pattern. DL is the interval from upper esophageal sphincter relaxation to the contractile deceleration point (CDP); a value less than 4.5 s defines a premature contraction. In non-symptomatic controls, it takes more than 4.5 s for a peristaltic wave to reach the CDP. The CDP is the inflexion point in the contractile front propagation velocity in the distal esophagus. The distal contractile integral (DCI) is also another indicator of the contraction pattern, particularly for the assessment of peristaltic strength. If hypercontractility involves the LES area, it was suggested to incorporate the LES into the DCI measurement domain.
At present, several catheter types and accompanying computer systems are available for HRM; thus, the different parameter cut off values between these products should be interpreted appropriately [26] . For example, an IRP [ 15 mmHg for achalasia diagnosis should only be used for the Medtronic system. Patient positioning for the procedure as sitting vs supine is also a concern [27] . The CC defines achalasia as insufficient relaxation of the LES (IRP [ upper limit of normal) and no normal peristalsis. Based on this classification, achalasia is categorized into the following three subtypes: type I (classic achalasia), mean IRP [ upper limit of normal (a common finding in all achalasia subtypes), and 100% failed peristalsis; type II, no normal peristalsis, and pan-esophageal pressurization with C 20% of swallows; type III, no normal peristalsis, and preserved fragments of distal peristalsis or premature (spastic) contractions with C 20% of swallows (Fig. 5 ).
Histopathology of achalasia
Previously, histological examination via Heller's myotomy [28] , surgical esophageal resection, or autopsy revealed the common findings of degeneration of the Auerbach plexus or interstitial cells of cajal (ICCs), and fibrotic tissue replacement in the esophageal muscle layer in achalasia [29] [30] [31] [32] [33] [34] . Inflammation was also observed, although there was some variation regarding the inflammatory cell type (mostly lymphocytes and, to a lesser extent, eosinophils).
Moreover, the infiltrate was patchy; therefore, specimen infiltration was related to sample size [34] [35] [36] . Although the manometric subtype of these reports was unknown, most of these reports likely showed histological findings of type I (classic) achalasia because of the sampling bias seen with surgical cases of long disease duration or those with severe symptoms. Recently, Sodikoff et al. retrospectively analyzed the conventional manometry pattern in patients with achalasia according to the CC and compared it with surgical specimens. They reported a greater degree, but similar pattern of ganglion cell loss observed in type I compared to that in type II, and suggested the pathology that type I achalasia represents a progression from type II achalasia [37] . We prospectively collected data of HRM and compared with the findings from muscle layer specimens obtained via a novel endoscopic technique, POEM-b, as described before. Our study showed that type I and II achalasia had a similarly reduced number of ICCs compared to a preserved number in type III, and severe fibrosis was only observed in type I (Fig. 3c-e) [38] . Although the correlation between the manometric subtypes and histopathology in achalasia has yet to be clarified, Kahrilas and Boeckxstaens reported that type III achalasia is likely a postganglionic nerve disorder with preservation or even augmentation of vagal extrinsic cholinergic modulation along the entire length of the smooth muscle portion of the esophagus. Conversely, type I (classic) achalasia with no post-deglutitive contractility is likely the consequence of nearly complete aganglionosis. Type II achalasia falls between these extreme patterns [39] . Because classic achalasia (not subtyped as type I in old reports) has a loss of the Auerbach plexus and lymphocytedominant inflammation, many studies using animal models and patient samples were performed to investigate the unknown etiology. Viral infection, autoimmune mechanism, and genetic factors were found to be related to achalasia; however, a definitive factor has not been discovered (Fig. 4) [40] [41] [42] [43] [44] [45] [46] .
Pathophysiology-based treatment of achalasia
Curative therapies are currently not available for achalasia. However, fortunately, satisfactory long-term outcomes with pneumatic dilation (PD) or laparoscopic Heller myotomy (LHM), and, to a lesser extent, botulinum toxin e Vacuolization of the myocyte cytoplasm in the muscularis propria is observed in advanced cases of achalasia, which reportedly may be a degenerative change related to ischemia [34] . f Eosinophilic infiltration in the perivascular and perimysial areas in some cases of JE (EoEM)
injection have been reported for the esophagus-localized benign disorder [47, 48] . Although it varies by study design, a multicenter randomized controlled trial in Europe showed an 84 and 82% success rate after 5 years for LHM and PD, respectively [49] . The defining characteristic in the pathophysiology of achalasia is a loss of LES relaxation, and the release from LES pressurization is considered vitally important for a satisfactory outcome. Recently, outcomes of achalasia treatment based on the manometric subtypes were reported. In a recent European trial using either PD or LHM for treatment of achalasia, success rates were significantly higher among patients with type II achalasia (96%) than type I achalasia (81%; P \ 0.01) or type III achalasia (66%; P \ 0.001). All patients with type III who were enrolled had persistent esophageal spasm during the follow-up period (although LES pressure was reduced), which is considered one reason for poor outcomes in type III [50] . The same conclusion for type III was driven by a meta-analysis of the correlation between treatment options and achalasia subtypes, where poor outcomes were also seen [51] . PD is effective only for tight LES, but not for abnormal contraction in the esophageal body. Furthermore, LHM may have been incompletely performed on the esophageal side due to limited surgical access from the gastric side. In contrast, a unique advantage of POEM over surgical LHM is that the length of the myotomy from the esophageal to gastric side can be adjusted freely based on the individual, because POEM is a peroral transluminal procedure [52] . Based on this, type III achalasia is expected to respond best to POEM. Khashab et al. reported a 93% clinical positive response for POEM to spastic disorders including type III achalasia in a [ 6-month follow-up period [53] . Further study with random allocation or with a long-term follow-up period is required to determine the advantages of POEM. A meta-analysis showed the rates of symptomatic GERD and esophagitis on gastroscopy were 8.5 and 13%, respectively, after a shortterm follow-up after POEM [54] .
EGJOO, DES, and JE
Manometric definition of EGJOO and the spastic disorders, DES and JE Esophago-gastric junction outflow obstruction (EGJOO) is defined as an elevated IRP, with sufficient evidence of peristalsis such that the criteria for types I-III achalasia are not met. Several studies suggest a potential etiology of EGJOO to include an early form of achalasia, or a spontaneous recovery form with a return to normal; therefore, heterogeneous groups could be included in this pathological category (Fig. 6a) [55, 56] .
Distal esophageal spasm (DES) is the most well-known esophageal spastic disorder. Although the term 'diffuse esophageal spasm' was obscurely used before, subsequent studies indicated that simultaneous contractions primarily in the distal esophagus, not in the proximal esophagus, occurred, and the term 'DES' and manometric definition of DES were established as a normal median IRP, with C 20% premature contractions (DL \ 4.5 s) (Fig. 6b ) [57, 58] .
The definition of a hyper-contractile esophagus (Jackhammer esophagus [JE] ) is based on C 20% of swallows with a DCI [ 8000 mmHg s cm with normal DL (Fig. 7a ) [59] . Nutcracker esophagus (NE), with a mean DCI [ 5,000 mmHg s cm without meeting the criteria for JE, was once defined by the CC but removed in version 3.0 because the clinical significance of the hypertensive peristaltic contractions was questioned. It has been reported that EGJOO, DES and JE might progress to achalasia [60, 61] .
Histopathology of these esophageal motility disorders
Few studies have been performed investigating the histopathology of EGJOO, DES, and JE because the manometric criteria were very recently clarified by the CC [37, 62] , and the pool of individuals with these disorders is small.
We firstly reported a heterogeneous histology of NE/JE with or without eosinophil infiltration in the esophageal muscle layer; one with eosinophil infiltration was named eosinophilic esophageal myositis (EoEM) (Fig. 3f ) [63] [64] [65] . Another esophageal eosinophilic disease, eosinophilic esophagitis (EoE), is known as a Th2-mediated allergy disorder. In EoE, eosinophils infiltrate the esophageal epithelium, and non-specific esophageal motility dysfunction is observed on HRM [66] [67] [68] [69] . Our cases of NE/JE, otherwise known as 'EoEM', had eosinophil infiltration localized in the esophageal muscle layer, but did not involve the esophageal epithelium; moreover, immunostaining and gene expression analysis showed a considerably different pathology between EoEM and EoE [70, 71] . Funaki et al. reported a case of DES (diagnosed using 8-channel conventional manometry with infused catheter system), suspected as allergy-induced, responded to systemic steroid therapy [72] . This intriguing case showed no eosinophil infiltration in the esophageal epithelium on random biopsy; therefore, it was not diagnosed as EoE, but possibly EoEM. A case of a patient diagnosed with EoEM using endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) was also reported [73] , and systemic steroid alleviated his symptoms and reduced the intensity of esophageal contractions (Fig. 7b) . Although the pathogenesis of esophageal spastic motility disorders is considered heterogeneous and includes non-eosinophil-related cases, some of these cases may be related to eosinophil infiltration in the histopathology (Fig. 4) . In the lower part of the intestine, eosinophilic myenteric ganglionitis, with systemic steroid responsive, was reported [74] .
Pathophysiology-based treatment of esophageal spastic disorders
Pharmacological treatment such as nitrates and calcium channel blockers both reduce LES pressure and esophageal contraction amplitude, which is considered effective for achalasia as well as esophageal spastic disorders [68] .
As type III achalasia (with spastic contraction) responds well to POEM, and POEM is expected to be a promising therapy for other esophageal spastic disorders such as DES and JE [53] , because premature contraction and hypercontraction, respectively, are the cornerstones of the pathophysiology, which can be best targeted with POEM (Fig. 4) . EGJOO, the pathophysiology which is a loss or incomplete relaxation of the LES, can be treated using PD, LHM, or POEM [75] .
In EoEM, systemic steroid therapy alleviated esophageal symptoms by mitigating esophageal hypercontraction, although systemic adverse events may prevent its longterm use [65] . In our practice, the long-term outcome of POEM was acceptable for dysphagia with complete resolution of esophageal hypercontraction in five patients with EoEM (follow-up period, 1-3 years) (Fig. 7c) . Two patients continued to have chest pain once every two to 3 months; however, the frequency, intensity, and duration were all substantially reduced compared to that before POEM.
Conclusion
A variety of esophageal functional disorders are now categorized using the CC. HRM has become a gold standard for diagnosis and clinical decision making. Moreover, POEM has enabled a minimally invasive effective treatment for more esophageal motility disorders, and during-POEM biopsy may become a major practice in histopathology, and is expected to provide new insights. At present, POEM appears to be an effective treatment for achalasia, EGJOO, DES, and JE. However, it may cause irreversible fibrotic change in the esophageal muscle layer, particularly in the LES [76] , and could induce post-POEM gastroesophageal reflux disease [77, 78] . Further study is needed to elucidate the pathology and etiology of these complicated esophageal motility disorders, and allow for the development of a curative treatment.
